BioCentury
ARTICLE | Company News

Cue Biopharma in autoimmune deal with Merck

November 16, 2017 8:23 PM UTC

Merck & Co. Inc. (NYSE:MRK) partnered with Cue Biopharma Inc. (Cambridge, Mass.) to develop biologics to treat autoimmune diseases.

Cue will receive an undisclosed upfront payment, and will be eligible for up to $374 million in milestones, plus tiered royalties...